On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Enters Joint Development Agreement with Noramco Inc.

Company: Willow Biosciences Inc. (WLLW)
Category: News

Willow Biosciences Inc. (CSE: WLLW), a leading developer of biosynthetic production systems for plant-derived active pharmaceutical ingredients (APIs) and intermediates, in early June announced its entry into an exclusive joint development agreement with Noramco Inc., a leading manufacturer of cannabinoids. Per the update, the two firms intend to collaboratively develop a yeast-based biosynthesis platform for the production and distribution of cannabidiol. Willow further notes that the work conducted through the agreement has the potential to open new and larger markets for CBD and related compounds. “Noramco is a world-class organization with a long history of developing APIs across numerous markets and is the market leader in synthetically-produced CBD,” Dr. Joseph Tucker, executive chairman of Willow, stated in the news release. “They are the obvious first choice as a partner to scale the development of our CBD biosynthesis program. Noramco’s global leadership in the production and sales of cannabinoids to pharmaceutical companies will naturally lead into manufacturing and sales into additional non-pharmaceutical markets.”

To view the full press release, visit http://nnw.fm/mDvS6

About Willow Biosciences Inc.

Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high value plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management, and CNS disorders. In the cannabinoid field, Willow owns proprietary yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC), and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at www.WillowBio.com

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://nnw.fm/WLLW

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Contact us: 212.418.1217